179.04
price up icon0.73%   1.30
after-market After Hours: 179.04
loading
Zoetis Inc stock is currently priced at $179.04, with a 24-hour trading volume of 1.57M. It has seen a +0.73% increased in the last 24 hours and a +1.81% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $176.8 pivot point. If it approaches the $179.5 resistance level, significant changes may occur.
Previous Close:
$177.74
Open:
$179
24h Volume:
1.57M
Market Cap:
$81.70B
Revenue:
$8.73B
Net Income/Loss:
$2.39B
P/E Ratio:
36.39
EPS:
4.92
Net Cash Flow:
$1.75B
1W Performance:
+2.33%
1M Performance:
+1.81%
6M Performance:
-10.00%
1Y Performance:
+4.18%
1D Range:
Value
$177.81
$179.71
52W Range:
Value
$144.80
$201.92

Zoetis Inc Stock (ZTS) Company Profile

Name
Name
Zoetis Inc
Name
Phone
973-822-7000
Name
Address
10 SYLVAN WAY, PARSIPPANY, NJ
Name
Employee
14,100
Name
Twitter
@zoetis
Name
Next Earnings Date
2024-08-06
Name
Latest SEC Filings
Name
ZTS's Discussions on Twitter

Zoetis Inc Stock (ZTS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-12-24 Reiterated Stifel Buy
Dec-19-23 Resumed Jefferies Buy
Dec-07-23 Initiated Exane BNP Paribas Outperform
Sep-06-23 Initiated HSBC Securities Buy
Jul-12-22 Initiated Piper Sandler Overweight
Nov-18-21 Initiated Morgan Stanley Overweight
Aug-05-21 Resumed Credit Suisse Outperform
Jul-16-21 Downgrade Raymond James Outperform → Mkt Perform
Mar-08-21 Upgrade BofA Securities Neutral → Buy
Mar-08-21 Upgrade Raymond James Mkt Perform → Outperform
Sep-21-20 Initiated Atlantic Equities Overweight
Aug-14-20 Upgrade Edward Jones Hold → Buy
Aug-12-20 Downgrade Gabelli & Co Buy → Hold
May-27-20 Initiated Jefferies Buy
Jan-10-20 Initiated Raymond James Mkt Perform
Sep-09-19 Initiated Goldman Buy
Jul-01-19 Downgrade BofA/Merrill Buy → Neutral
Jun-11-19 Initiated Barclays Overweight
May-23-19 Initiated Guggenheim Buy
May-03-19 Downgrade Gabelli & Co Buy → Hold
Mar-20-19 Initiated SunTrust Hold
Mar-04-19 Upgrade Stifel Hold → Buy
Jan-23-19 Initiated UBS Neutral
Oct-15-18 Upgrade JP Morgan Neutral → Overweight
Aug-22-18 Downgrade Stifel Buy → Hold
Aug-03-18 Reiterated Stifel Buy
Apr-19-18 Reiterated Citigroup Buy
Mar-19-18 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-16-18 Reiterated Stifel Buy
Jan-04-18 Upgrade Citigroup Neutral → Buy
View All

Zoetis Inc Stock (ZTS) Financials Data

Zoetis Inc (ZTS) Revenue 2024

ZTS reported a revenue (TTM) of $8.73 billion for the quarter ending March 31, 2024, a +7.91% rise year-over-year.
loading

Zoetis Inc (ZTS) Net Income 2024

ZTS net income (TTM) was $2.39 billion for the quarter ending March 31, 2024, a +15.45% increase year-over-year.
loading

Zoetis Inc (ZTS) Cash Flow 2024

ZTS recorded a free cash flow (TTM) of $1.75 billion for the quarter ending March 31, 2024, a +20.03% increase year-over-year.
loading

Zoetis Inc (ZTS) Earnings per Share 2024

ZTS earnings per share (TTM) was $5.19 for the quarter ending March 31, 2024, a +17.16% growth year-over-year.
loading

Zoetis Inc Stock (ZTS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Lagano Roxanne
Executive Vice President
Apr 18 '24
Sale
151.17
923
139,530
14,800
Lagano Roxanne
Executive Vice President
Mar 18 '24
Sale
173.33
923
159,984
15,723
Reed Willie M
Director
Mar 11 '24
Sale
182.68
1,370
250,265
9,994
PECK KRISTIN C
Chief Executive Officer
Feb 20 '24
Option Exercise
46.09
13,000
599,170
92,366
PECK KRISTIN C
Chief Executive Officer
Feb 20 '24
Sale
187.20
13,000
2,433,636
79,366
Lagano Roxanne
Executive Vice President
Feb 20 '24
Sale
187.30
923
172,878
16,646
Lagano Roxanne
Executive Vice President
Feb 13 '24
Sale
186.86
2,848
532,177
17,569
Lagano Roxanne
Executive Vice President
Feb 12 '24
Sale
197.74
363
71,780
20,417
Lagano Roxanne
Executive Vice President
Jan 18 '24
Sale
191.43
923
176,690
17,569
Lagano Roxanne
Executive Vice President
Dec 18 '23
Sale
198.14
923
182,883
18,492
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
drug_manufacturers_specialty_generic TAK
$13.44
price up icon 0.30%
drug_manufacturers_specialty_generic HLN
$8.90
price up icon 1.14%
$17.28
price up icon 1.05%
$147.43
price up icon 0.63%
$11.24
price up icon 0.45%
Cap:     |  Volume (24h):